Multiple Class Action Lawsuits Filed on Behalf of Shareholders Against Mylan


A number of law firms filed separate class action lawsuits on behalf of shareholders last week against Mylan BV, the marketers of the EpiPen auto-injector.

The complaints are a result of Mylan agreeing to pay $465 million to settle claims by the Justice Department that the company had overcharged Medicaid and Medicare by misclassifying EpiPen as a generic drug and by doing so reduced discounts due the government from 23% to 13% for $1.3 billion spent on the device.

Click to visit sponsor

The complaints all make similar claims against Mylan as described in a press release from Pomerantz LLP, alleging that:

Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:

  1. Mylan paid Medicaid significantly lower EpiPen rebates than legally required;
  2. Medicaid had previously advised Mylan of the Company’s obligation to pay higher rebates;
  3. Mylan therefore knowingly and systemically overcharged Medicaid for EpiPens in violation of federal law;
  4. millions of dollars of Mylan’s revenue from EpiPen sales were the result of the foregoing illegal conduct by the Company; and
  5. as a result of the foregoing, Mylan’s public statements were materially false and misleading at all relevant times.

Other firms announcing actions on behalf of shareholders are Bronstein, Gewirtz & Grossman, LLC and Bernstein Liebhard, LLP.

Print or share this article
Print or share this article
Click to visit sponsor
Dave Bloom
Dave Bloom
Dave Bloom is CEO and "Blogger in Chief" of

Find Allergy-Friendly Products


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.